User blogs
LG CNS launches AI robot subscription service for warehouse operators
LG CNS unveiled a cloud-based logistics robot subscription service on Tuesday, which could save warehouse operators a significant amount in upfront cosst. To get more news about Robot Subscription, you can visit glprobotics.com official website.
The conglomerate’s information technology arm dubbed its new service Robot as a Service (RaaS), which allows customers to pay in installments at annual subscription fees during the contract period.
The LG Corp. subsidiary plans to provide customized automated robots based on the logistics centers’ size and purpose.
Included in the subscription will be a remote warehouse control system using the cloud and the internet of things (IoT) technologies. The aim is to expedite the shipping process and optimize the management of robots through data analytics.
"We will incorporate multiple technologies involved in digital transformation (DX) such as cloud, artificial intelligence, and data with robotics, which would enable more customers to actualize their logistics intelligence," LG CNS smarts logistics business head Lee Jun-ho said in a statement on Tuesday.
Founded in 1987, LG CNS has a whopping 30% market share in South Korea’s automated logistics market, estimated to be around 810 billion won ($625 million).
The company provides a whole gamut of logistics automation robots including Autostore, a cube-type logistics robot that can store, load, and move products; AI picking robot that accurately picks up products using artificial intelligence; Automated Guided Vehicle (AGV) that repeatedly transports products on a fixed route; as well as Autonomous Mobile Robot (AMR) that transports and loads products by navigating the route using the equipped sensors.
Robots as a Service (RaaS) – everything you need to know
Robots as a Service (RaaS) has become popular in the last couple of years mainly because it is much cheaper for a business to hire a robot for a specific project than to buy one that it may not fully utilize in the long run. For purpose of efficiency and effectiveness, most robot arms are usually designed to do a particular task, such as moving items from one position to another.To get more news about GRS, you can visit glprobotics.com official website.
Besides costs, there are several other advantages of RaaS over buying an in-house robot. In this article, we will discuss everything you need to know about RaaS, including its benefits and the different types of robots that you can hire.
What is Robots as a Service?
It is a service that involves hiring robots to organizations that would like to use robots but do not have the expertise or in-house recourses to procure and maintain these robots. There are several types of robots that organizations can hire depending on the task at hand. Some of the popular options include robot arms, cobots, and universal robots.
Robot arms are designed with almost the same functionality as a human arm. Their core task is to handle and move things from one position to another. A cobot or collaborative robot is designed to work hand in hand with humans. Universal robots are more versatile robot arms that can do more tasks than the standard robot arms.
Use cases of RaaS
Temporary warehouse operations: If you have a temporary project that involves operating a warehouse, it is much wiser to hire robots than buy them. Robots are more efficient and less costly to maintain than humans. However, you could also use cobots that work with humans to handle different warehouse operations.
Security for structures under construction: You can use robots to do the 360o surveillance of facilities under construction. Robots capture useful real-time information that can be sent to AI algorithms for further interpretation.
Benefits of RaaS
Lower costs of entry: small businesses that don’t have the money to buy robots can take advantage of RaaS by hiring robots for handling specific projects that humans may not be effective and efficient at.
Increased scalability: Businesses can quickly scale up their automation operations using some of the cutting-edge robotic technologies without incurring high upfront costs and the risk of asset deterioration or obsolescence.
Businesses no longer need robotic experts: With RaaS, small businesses can hire robots without having to recruit robotics professionals. Most of the configurations are done on the cloud by the RaaS provider. This further lowers the barrier of entry for getting into the automation space.
Final thoughts
If your business operations involve tasks that can be done by robot arms, cobots, or universal robots, using RaaS is the easiest way to get started. The good news is that you can hire cobots from Bots.co.uk for as low as £65 a day. Considering how much work these robots can do in a day, £65 is a worthy investment if your business has enough operations that need to be automated.
Global Robot Report 2021 presented
The first version of our report 'World Robotics R&D Programs' was presented in June last year. Since then, dozen of countries have updated their robotics research and development programs, "says Prof. Dr. Jong-Oh Park, IFR Research Committee Vice-Chair and Executive Board member." The five most advanced robotics countries - South Korea, Japan, Germany , USA and China - have very different strategic focuses. "To get more news about GRS, you can visit glprobotics.com official website.
The strategic plan "Made in China 2025" serves as a blueprint for improving the manufacturing capacities of Chinese industry. In order to promote the rapid development of intelligent robot technology, the important special program "Intelligent Robots" was launched, which includes the innovation chain. The focus is on fundamental, cutting-edge technologies of intelligent robots, new generation robots, common key technologies, industrial robots, service robots and special robots. The development goals are based on continuous growth in industrial use. China wants to develop at least three leading companies with international competitiveness and create more than five clusters of robot-assisting industries. The statistical yearbook "World Robotics" of the International Federation of Robotics shows that China has already achieved a robot density of 187 units per 10,000 workers in the manufacturing industry - this puts the country in 15th place worldwide.
In Japan, the "New Robot Strategy" aims to make the country the world's number one in the field of robot innovation. The rate of robotization in the manufacturing sector is to be increased by 25 percent for large companies and 10 percent for SMEs. An important performance indicator is also to expand the market for system integrators - they work as an intermediary between manufacturer and user. The action plan covers important areas of service robotics such as agriculture, infrastructure and healthcare. The nursing & medical sector alone has a budget of US $ 997.3 million and supports the health data reform through practical robot applications and the use of artificial intelligence. According to the statistical yearbook "World Robotics" of the International Federation of Robotics, Japan is the world's leading manufacturer of industrial robots and in 2019 covered a total of 47 percent of global demand.
With the “Intelligent Robot Development and Supply Promotion Act”, South Korea is promoting the development of the country's robot industry as the core industry of the fourth industrial revolution. Areas of focus are manufacturing operations (with a special program to increase the competitiveness of SME manufacturing locations), certain areas of service robotics (including healthcare and logistics), and key components and software for robots. For the intergovernmental project "Full Cycle Medical Device Development" the government plans a budget of 1.07 billion US dollars (1.2 trillion KRW) from 2020 to 2025. The statistical yearbook "World Robotics" of the International Federation of Robotics shows set a new record number of around 319,000 industrial robots in South Korea for 2019 (+13 percent). Within five years, the country has doubled the number of its industrial robots in operation. In 2019, the country took third place after Japan and China.
The new European framework program Horizon Europe promotes research and innovation in the period from 2021 to 2027. Building on the results and successes of Horizon 2020, the new edition supports top research, innovators and the general public in providing knowledge and solutions for a green, digital and healthy future develop. The robotics work program is embedded in Cluster 4 “Digital, Industry and Space”. Robotics R&D projects focus on digital change in manufacturing and construction, autonomous solutions to support workers, improved cognition and human-robot collaboration. The robotics-specific work program 2021-2022 in Cluster 4 will provide a total of 240 million US dollars (198.7 million euros).
The high-tech strategy 2025 in Germany is the fourth edition of the German research and innovation program. The aim is to quickly turn good ideas into innovative products and services. Most of the framework program promotes partnerships between companies, universities and research institutions in order to bring together institutional research and entrepreneurial expertise. By 2025, 3.5 percent of GDP is to be invested in research and development every year. Under the mission “Technology for People”, among other things, the “Together through Innovation” program was launched in 2020, which promotes interactive technologies for health and quality of life. With this research program, the Federal Ministry of Education and Research (BMBF) will provide around 84 million a year until 2026 US dollars (70 million euros) are available.
In the USA, the National Robotics Initiative (NRI) was set up by the US government to support research and development in the field of robotics. The NRI-2.0 promotes collaboration between academic, industrial, non-profit and other organizations in order to achieve a better connection between basic science, engineering, technology development, deployment and use. Space robotics forms a key sector with the “Artemis” lunar program. Artemis' goal is to bring astronauts back to the lunar surface by 2024 and to develop promising resources for Mars missions in the period after 2024. Artemis is a joint space program of NASA and international partners such as ESA (consisting of 22 countries), Canada, Japan and Russia. The US government plans a budget of 35 billion US dollars for the years 2020 to 2024. The largest donor for the development of unmanned systems including robotics is still the US Department of Defense (DoD) with a planned budget of 7.3 billion US dollars in the years 2020 and 2021. According to the international statistical yearbook "World Robotics" Federation of Robotics, the robot density in the US manufacturing industry grew by 7 percent (CAGR) from 2014 to 2019 with 228 robots per 10,000 employees - 9th place worldwide. In terms of annual installations of industrial robots, the country ranks third.
REPLACE COVID Bolsters Advice to Continue RAAS Inhibitors in COVID-19 Patients
Another randomized trial, REPLACE COVID, indicates that patients already taking ACE inhibitors and ARBs when they’re hospitalized for COVID-19 should continue to do so, supporting recommendations from international CV societies.To get more news about RaaS, you can visit glprobotics.com official website.
When it came to outcomes including all-cause death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during hospitalization, there were no differences between patients who continued versus discontinued their renin-angiotensin-aldosterone-system (RAAS) inhibitors after they were admitted, researchers report in a study published online last week in the Lancet Respiratory Medicine.
Considering these findings and those from the BRACE CORONA trial, presented last year at the virtual European Society of Cardiology Congress, the message is simple, according to senior author Julio Chirinos, MD, PhD (University of Pennsylvania, Philadelphia). “In people who fall ill with COVID-19 requiring hospital admission, continuing these medications for established indications should be considered safe.”
Early after SARS-CoV-2 started circulating around the world, there were concerns that use of RAAS inhibitors might worsen the severity of COVID-19. That’s because there was some evidence that the agents increase the expression of ACE2, which has been shown to facilitate entry of the novel coronavirus into host cells.
International CV societies came out in favor of continuing ACE inhibitors and ARBs in patients hospitalized with COVID-19 while acknowledging the need for better data exploring the issue. Subsequent observational studies mostly suggested that there was no relationship between outpatient use of RAAS inhibitors and risk of COVID-19 hospitalizations or mortality, but randomized trials were launched to provide more-definitive insights.
REPLACE COVID, co-led by Chirinos and Jordana Cohen, MD (University of Pennsylvania), was a randomized, open-label trial conducted at 20 hospitals in the United States, Canada, Mexico, Sweden, Peru, Bolivia, and Argentina. It included 152 hypertensive patients (mean age 62 years; 45% women) randomized to continue or discontinue their ACE inhibitors and ARBs.
The primary outcome consisted of a global rank score that incorporated time to death; duration of mechanical ventilation or extracorporeal membrane oxygenation; time on renal replacement or inotropic or vasopressor therapy; and multiorgan dysfunction during hospitalization, assessed with the modified Sequential Organ Failure Assessment (SOFA) score. The global rank score did not significantly differ between the continuation and discontinuation arms (median 73 vs 81; P = 0.61).
There were also no differences in any of the secondary outcomes, including all-cause death (15% vs 13%; P = 0.99) and median length of the hospital stay (6 vs 5 days; P = 0.56).
Adverse events occurred in 39% of patients who continued their RAAS inhibitors and 36% of those who stopped taking them (P = 0.77). Blood pressure and serum levels of potassium and creatinine during follow-up were similar in the two trial arms.
“Our findings, derived from a prospective, multicenter, randomized, controlled design, are consistent with previously published observational studies and unpublished trial evidence, which have generally shown no difference in the risk of SARS-CoV-2 infection and COVID-19 severity among patients who are treated with ACE inhibitors or ARBs compared with those who are not,” the authors conclude.